It was a great month to be a genetic testing company.
News & Analysis: Exact Sciences
EXAS earnings call for the period ending June 30, 2019.
At first glance, an acquisition announcement looked like the wrong deal.
Shares are heading in opposite directions after the two cancer diagnostic companies surprised Wall Street by revealing plans to merge. Here's what investors need to know.
The biotech's recent momentum is showing no signs of cooling off, despite its jaw-dropping valuation.
Easier ways to look for solid tumors are closer than you think.
These look like great picks to buy in May before you go away.
A new study is planned that could someday reshape colon cancer screenings.
Exact Sciences stock hit an all-time high last month, despite a sour market for biotech stocks.
EXAS earnings call for the period ending March 31, 2019.